ClavystBio Emerges as Gateway to Asia’s Thriving Life Sciences Ecosystem

When Australian biotech executives and researchers touch down in Singapore later this year as part of Informa Australia’s life sciences trade mission, one destination on their itinerary stands out as particularly promising: ClavystBio, a powerhouse investor and venture builder that’s rapidly transforming Singapore into a global biotech hub.

Established by Temasek, Singapore’s sovereign wealth fund, ClavystBio has quickly built a reputation for identifying breakthrough innovations and accelerating their path to commercial success and health impact. For Australian companies looking to expand their footprint in Asia, this visit represents a rare opportunity to engage directly with one of the region’s most influential life sciences investors.

“ClavystBio doesn’t just provide capital—they build companies designed to succeed globally while maintaining strong roots in Singapore,” notes the trade mission organizer. “Their model of combining investment with hands-on venture building makes them an ideal partner for Australian innovators seeking to scale across Asia.”

A Track Record of Success

What makes ClavystBio particularly attractive to potential Australian partners is their impressive portfolio performance. In just the first five months of 2025, four ClavystBio portfolio companies secured major financing rounds with global investment syndicates.

Nuevocor, an A*STAR spin-off pioneering genetic cardiomyopathy therapies, raised $45 million in Series B financing from investors including ClavystBio, Boehringer Ingelheim Venture Fund, and EDBI. The company recently received FDA clearance for its first program and will begin clinical trials in the US in early 2026.

Allay Therapeutics, focused on post-surgical pain management, secured $57 million in Series D financing co-led by ClavystBio and US investor Lightstone Ventures. Their innovative non-opioid solution provides pain relief for up to 30 days—a dramatic improvement over the current standard of 3-4 days.

Perhaps most impressive is Callio Therapeutics, which raised an extraordinary $187 million Series A from a global syndicate including ClavystBio, EDBI, Frazier, Novo Holdings, and Jeito. This spin-out from Singapore’s Hummingbird Bioscience is developing cancer-specific Antibody Drug Conjugate therapies.

The Singapore Advantage

ClavystBio’s collaborative space, Node 1, located at Singapore Science Park, offers more than just investment opportunities. It provides a vibrant ecosystem where companies that have outgrown incubators can continue their development journey with appropriate support.

What makes ClavystBio unique is their commitment to building global companies from Singapore. They’ve mastered the art of connecting Asian innovation with global markets, something that’s particularly valuable for Australian companies looking to expand beyond domestic borders.

Australia-Singapore Synergies

The potential for collaboration between Australian and Singaporean life sciences companies is substantial and represents a key focus of the trade mission. Australia’s robust clinical trial infrastructure presents a significant advantage for Singapore-based biotechs, particularly for critical first-in-human studies that can accelerate development timelines.

ClavystBio has already demonstrated the power of such cross-border collaboration through portfolio company Automera, whose foundational innovation originated in Australia before being developed further in Singapore. This model of combining scientific excellence and intellectual property from both ecosystems creates stronger platforms and novel assets that benefit from the complementary strengths of each country.

The trade mission will also highlight opportunities for strategic talent exchange in key areas like clinical development, drug development, and executive leadership—creating a powerful synergy that enhances innovation and commercial success for companies in both countries.

There’s tremendous complementarity between these ecosystems. Australian scientific excellence combined with Singapore’s development capabilities and access to Asian markets creates opportunities that neither country could realize independently.

Beyond Investment: Building Capabilities

For Australian delegates, the visit to ClavystBio represents more than just a funding opportunity. It’s a chance to understand how Singapore is building specialized capabilities in therapeutics, digital health, and medtech—with an emphasis on first-in-class science and technology.

The trade mission’s carefully curated program ensures participants gain insights into ClavystBio’s investment philosophy and venture-building approach, potentially opening doors for future partnerships.

A Strategic Stop on a Comprehensive Journey

As part of Informa Australia’s four-day program surrounding the Asia Bio Partnering Forum, the ClavystBio visit exemplifies the trade mission’s commitment to providing delegates with access to key industry stakeholders beyond the conference itself.

For Australian biotech companies, clinical research organizations, universities, medical research institutes, and government representatives, this represents a unique opportunity to engage with one of Asia’s most dynamic life sciences investors in their home environment.

With ClavystBio’s impressive track record of building globally competitive companies from Singapore, Australian delegates stand to gain valuable insights, connections, and potentially, investment partners who understand how to bridge Western innovation with Asian market opportunities.

The Informa Australia life sciences trade mission to Singapore will take place from the 8-11 September this year, featuring the Asia Bio Partnering Forum and additional programming designed to connect Australian organizations with Singapore’s thriving life sciences ecosystem.